Ostrum Asset Management’s Royalty Pharma RPRX Stock Holding History

Ostrum Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.57M	Sell	99,352 -2,463	-2%	-$128K	0.27%	52
2026 Q1	$4.88M	Buy	101,815 +24,502	+32%	+$1.07M	0.27%	52
2025 Q4	$2.99M	Sell	77,313 -1,533	-2%	-$58.5K	0.14%	114
2025 Q3	$2.78M	Buy	78,846 +9,154	+13%	+$331K	0.13%	146
2025 Q2	$2.51M	Buy	69,692 +7,842	+13%	+$260K	0.12%	162
2025 Q1	$1.93M	Sell	61,850 -33,982	-35%	-$1.08M	0.1%	198
2024 Q4	$2.44M	Sell	95,832 -53,820	-36%	-$1.43M	0.21%	151
2024 Q3	$4.23M	Buy	149,652 +16,757	+13%	+$464K	0.35%	61
2024 Q2	$3.5M	Sell	132,895 -27,586	-17%	-$765K	0.31%	82
2024 Q1	$4.87M	Hold	160,481	–	–	0.39%	56
2023 Q4	$4.51M	Buy	160,481 +20,216	+14%	+$556K	0.39%	64
2023 Q3	$3.81M	Sell	140,265 -28,399	-17%	-$843K	0.35%	64
2023 Q2	$5.18M	Sell	168,664 -672	-0.4%	-$22.8K	0.43%	50
2023 Q1	$6.1M	Buy	+169,336	New	+$6.28M	0.53%	35

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ostrum Asset Management's RPRX Position: Q2 2026 in Review

Ostrum Asset Management reduced its Royalty Pharma (RPRX) stake by 2.4% in Q2 2026, selling an estimated $128K and leaving 99,352 shares worth $5.57M. The position accounts for 0.27% of the portfolio, ranked #52.

Ostrum Asset Management first reported a position in RPRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $6.1M in Q1 2023. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Ostrum Asset Management held 99,352 shares of Royalty Pharma worth $5.57M as of Q2 2026.
Ostrum Asset Management sold 2,463 Royalty Pharma shares in Q2 2026, an estimated $128K.
Royalty Pharma made up 0.27% of Ostrum Asset Management's portfolio in Q2 2026, its #52 holding.
Ostrum Asset Management first reported a position in Royalty Pharma in Q1 2023 and has held it in 14 quarters since.
Ostrum Asset Management's Royalty Pharma position peaked at $6.1M in Q1 2023.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ostrum Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.